HCPCS Level II code J1750 denotes a 50 mg injection of iron dextran, a parenteral iron therapy used to treat iron-deficiency when oral therapy is inadequate or intolerable. Nationally, injectable iron products are significant for managing anemia associated with chronic disease, renal failure, and other conditions where rapid repletion of iron stores is required. Accurate coding of J1750 affects claims processing, clinical documentation, and program-level tracking of parenteral iron utilization.

This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for J1750, typical sites of service, and the coding specifics necessary for claims. The publication summarizes common billing considerations, modifier usage patterns (listed separately), and related service-line implications. It also outlines benchmarking and policy-relevant items readers should monitor, such as coverage policies, prior authorization practices, and reimbursement norms for parenteral iron therapies.

The content is organized to support billing staff, revenue cycle teams, and policy analysts seeking a succinct reference on J1750—what the code represents, where it is used, and payer coverage scope at a national level.